Human milk glycosaminoglycans: the state of the art and future perspectives
© Coppa et al.; licensee BioMed Central Ltd. 2013
Received: 7 January 2013
Accepted: 10 January 2013
Published: 15 January 2013
Recently, a complete characterization and detailed evaluation of the glycosaminoglycans of human milk were performed. The total glycosaminoglycans content in milk from healthy mothers having delivered term or preterm newborns showed a constant pattern which was essentially composed of two main polysaccharides: chondroitin sulfate (60-70%) and heparin (30-40%). Moreover, considerable variations of glycosaminoglycans concentration were found during the first month of lactation, the highest values being present in colostrum compared to mature milk. Metabolism and potential biological functions of human milk glycosaminoglycans are hypothesized and future studies are encouraged.
In the last few decades consistent evidence has been reported on several human milk glycans (such as glycoproteins, glycolipids and especially oligosaccharides) which have been demonstrated to possess specific biological properties, positively influencing the breastfed newborn health [1–4]. On the contrary, only four studies are actually available in the literature on another family of complex carbohydrates, the glycosaminoglycans (GAGs) [5–8].
GAGs are linear heteropolysaccharides composed of a variable number of repeating disaccharidic units, which are able to regulate many cellular events and physiological processes (such as cell growth and differentiation, cell-cell and cell-matrix interaction, anti-infective and anti-inflammatory processes, etc.) [9–11]. On the basis of their structure and composition, GAGs are generally grouped into four main categories: 1) hyaluronic acid (HA); 2) chondroitin sulfates (CS) and dermatan sulfate (DS); (3) heparan sulfate (HS) and heparin (Hep); 4) keratan sulfate (KS).
State of the art
The first data reported in the literature on milk GAGs are those described by Shimizu et al. . Their study was not performed on whole milk but exclusively focused on milk fat globule membranes. The total GAG content was 5–10 times higher in human than in bovine milk membranes. Qualitative analyses on membranes from mature milk samples demonstrated that the major GAG in both bovine and human milk was HS (70%), with the remainder 30% represented by CS.
Further information on human milk GAG composition was later provided by the study done by Newburg et al. . Even if no quantitative data were reported, it was interestingly shown that GAGs isolated from human milk were able to play an important role as anti-infective agents.
GAGs quantitative evaluation in human and bovine milk
Total GAGs (mg/L)
Metabolism and potential biological functions
At the same level of the small intestine, the GAGs, due to their well-known properties, could contribute to the antioxidant effect of human milk, which is particularly important during the neonatal period. In fact, it has been demonstrated that CS (and other GAGs) are able to stimulate the pathway which induces the activation of antioxidant enzymes , and which is particularly important in preterm infants endowed with an immature defence system.
Furthermore, the undigested GAGs, reaching the colon, could behave as prebiotics, contributing to the development of bifidogenic flora as it has been demonstrated that bifidobacteria possess specific enzymes involved in the metabolism of carbohydrates .
Finally, a certain amount of undigested GAGs could be present in infant feces behaving as dietary fibers according to international definition.
From the review of the literature, it clearly emerges that further studies are necessary to explore the metabolic fate, the physiological role and other human milk GAGs possible positive effects on the newborn’s health. As for other glycan components such as oligosaccharides, further in vitro and in vivo studies should be performed to achieve more information on their possible antinfective, antioxidant and prebiotic effects.
Finally, new knowledge on human milk components is the starting basis for the preparation of improved infant formulas in the future.
- Hanson LA: Feeding and infant development breast-feeding and immune function. Proc Nutr Soc. 2007, 66: 384-396. 10.1017/S0029665107005654.View ArticlePubMedGoogle Scholar
- Newburg DS: Neonatal protection by an innate immune system of human milk consisting of oligosaccharides and glycans. J Anim Sci. 2009, 87 (Suppl 13): 26-34.PubMedGoogle Scholar
- Gabrielli O, Zampini L, Galeazzi T, Padella L, Santoro l, Peila C, Giuliani F, Bertino E, Fabris C, Coppa GV: Preterm milk oligosaccharides during the first month of lactation. Pediatrics. 2011, 128: e1520-e1531. 10.1542/peds.2011-1206.View ArticlePubMedGoogle Scholar
- Bode L: Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology. 2012, 22: 1147-1162. 10.1093/glycob/cws074.PubMed CentralView ArticlePubMedGoogle Scholar
- Shimizu M, Uryu N, Yamauchi K: Presence of heparin sulphate in the fat globule membrane of bovine and human milk. Agr Biol Chem. 1981, 45: 741-745. 10.1271/bbb1961.45.741.View ArticleGoogle Scholar
- Newburg DS, Linhardt RJ, Ampofo SA, Yolken RH: Human milk glycosaminoglycans inhibit HIV glycoprotein gp120 binding to its host cell CD4 receptor. J Nutr. 1995, 125: 419-424.PubMedGoogle Scholar
- Coppa GV, Gabrielli O, Buzzega D, Zampini L, Galeazzi T, Maccari F, Bertino E, Volpi N: Composition and structure elucidation of human milk glycosaminoglycans. Glycobiology. 2011, 21: 295-303. 10.1093/glycob/cwq164.View ArticlePubMedGoogle Scholar
- Coppa GV, Gabrielli O, Zampini L, Galeazzi T, Maccari F, Buzzega D, Galeotti F, Bertino E, Volpi N: Glycosaminoglycan content in term and preterm milk during the first month of lactation. Neonatology. 2012, 101: 74-76. 10.1159/000330848.View ArticlePubMedGoogle Scholar
- Jackson RJ, Bush SJ, Cardin AD: Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev. 1991, 71: 481-539.PubMedGoogle Scholar
- Raman R, Sasiseskharan V, Sasiseskharan R: Structural insites into biological roles of protein-glycacosaminoglycan interactions. Chem Biol. 2005, 12: 267-277. 10.1016/j.chembiol.2004.11.020.View ArticlePubMedGoogle Scholar
- Sasiseskharan R, Raman R, Prabhakar V: Glycomics approach to structure-finction relationships of glycosaminoglycans. Annu Rev Biomed Eng. 2006, 8: 181-231. 10.1146/annurev.bioeng.8.061505.095745.View ArticleGoogle Scholar
- Roughley PJ, Mort JS: Catabolism of proteoglycans. Proteoglycans: structure, biology and molecular interactions. Edited by: Iozzo RV. 2000, New York: Marcel Dekker Inc, 93-113.Google Scholar
- Coppa GV, Zampini l, Galeazzi T, Facinelli B, Ferrante L, Capretti R, Gabrielli O: Human milk oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens: Escherichia coli, Vibrio cholerae and Salmonella fyris. Pediatr Res. 2006, 59: 377-382. 10.1203/01.pdr.0000200805.45593.17.View ArticlePubMedGoogle Scholar
- Hill DR, Kessler SP, Rho HK, Cowman MK, de la Motte CA: Specific-sized hyaluronan fragments promote expression of human β-defensin 2 in intestinal epithelium. J Biol Chem. 2012, 287: 30610-30624. 10.1074/jbc.M112.356238.PubMed CentralView ArticlePubMedGoogle Scholar
- Egea J, Garcia AG, Verges J, Montell E, Lopez MG: Antioxidant antiinflammatory and neuroprotective actions of chondroitin sulphate and proteoglycans. Osteoarthritis Cartilage. 2010, 18: S24-S27.View ArticlePubMedGoogle Scholar
- Ventura M, Canchaya C, Fitzgerald GF, Gupta RS, Van Sinderen D: Genomics as a means to understand bacterial phylogeny and ecological adaptation: the case of bifidobacteria. Antonie Leeuwenhoek. 2007, 91: 351-371. 10.1007/s10482-006-9122-6.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.